中国药物经济学2026，Vol.21Issue(1)：66-68,75,4.DOI:10.12010/j.issn.1673-5846.2026.01.013
阿奇霉素联合哌拉西林他唑巴坦对重症肺炎患儿血清白细胞介素-6与C反应蛋白水平的影响
Influence of Azithromycin Combined with Piperacillin Tazobactam on the Levels of Serum Interleukin-6 and C-reactive Protein in Children with Severe Pneumonia
秦璇 1刘亚慧1
作者信息
- 1. 南京市江宁医院药学部,南京 211100
- 折叠
摘要
Abstract
Objective To explore the effect of azithromycin combined with piperacillin tazobactam on the levels of serum interleukin-6(IL-6)and C-reactive protein(CRP)in children with severe pneumonia.Methods A total of 101 children with severe pneumonia admitted to Jiangning Hospital in Nanjing from March 2022 to March 2025 were selected and divided into the control group(50 cases)and the observation group(51 cases)according to the random number table method.The control group was treated with piperacillin tazobactam,while the observation group was treated with azithromycin dry suspension on the basis of the control group.The treatment effective rate,symptom score,serum IL-6 and CRP levels of the two groups of children were compared.Results The effective rate of treatment in the observation group was 98.04%,which was higher than 84.00%in the control group,and the difference was statistically significant(P＜0.05).After treatment,the scores of fever,cough and expectoration,wheezing and pulmonary rales in the observation group were all lower than those in the control group(P＜0.05).The levels of serum IL-6 and CRP in the observation group after treatment were lower than those in the control group(P＜0.05).Conclusion The combined application of azithromycin on the basis of piperacillin tazobactam can significantly improve the overall therapeutic effect of children with severe pneumonia,effectively promote the rapid relief of clinical symptoms,significantly reduce the levels of serum IL-6 and CRP.关键词
重症肺炎/阿奇霉素/哌拉西林他唑巴坦/白细胞介素-6/C反应蛋白Key words
Severe pneumonia/Azithromycin/Piperacillin tazobactam/Interleukin-6/C-reactive protein分类
医药卫生引用本文复制引用
秦璇,刘亚慧..阿奇霉素联合哌拉西林他唑巴坦对重症肺炎患儿血清白细胞介素-6与C反应蛋白水平的影响[J].中国药物经济学,2026,21(1):66-68,75,4.
